• Explore /
  • Poster
  • / A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).

A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).

Abstract Poster

Authors

null

Hui Kong Gan

Austin Health and Ludwig Institute for Cancer Research, Melbourne, Australia

Hui Kong Gan , Lisa Fichtel , Andrew B. Lassman , Ryan Merrell , Martin J. Van Den Bent , Priya Kumthekar , Andrew Mark Scott , Michelle Pedersen , Erica Gomez , JuDee Fischer , William Ames , Hao Xiong , Matthew W. Dudley , Wijith Munasinghe , Lisa Roberts-Rapp , Peter Ansell , Kyle D. Holen , David A. Reardon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT01800695

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2021)

DOI

10.1200/jco.2014.32.15_suppl.2021

Abstract #

2021

Poster Bd #

11

Abstract Disclosures

Similar Posters

First Author: Hui K. Gan

First Author: Melissa Lynne Johnson

First Author: Frank Saran

First Author: Martin J. Van Den Bent